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Abstract The cGMP-dependent protein kinase hx (PKG Is)  
possesses two functional moieties, the regulatory and catalytic 
domains, which reside on a single polypeptide chain. Here we 
report on the influence of the catalytic domain on the binding of 
cGMP to the regulatory domain. A deletion mutant, A352-670 
of PKG I~ lacking the catalytic domain, was constructed and 
expressed in E. coil The purified 38 kDa mutant protein showed 
strong reactivity toward tryptic proteolysis at residue Arg 77. 
Thus, a double deletion fragment A1-771352-670 PKG Icx, 
lacking the N-terminus, was also purified. Both proteins had 
functional cGMP binding, but differed kinetically from the wild- 
type protein. First the affinity constants for cGMP were 
modulated, second the constructs howed no signs of cooperative 
cGMP binding and third dimerization of the A352-670 mutant 
was abolished. Our results provide evidence that the catalytic 
domain forms an intimate interaction with the regulatory domain 
and modulates the kinetics of cGMP binding. 
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cGMP off-rate paired with an apparent KD of 14-17 nM 
[13,14]. In addition, the cGMP-binding sites, as well as the 
cAMP-binding sites of PKA, show positive cooperativity for 
cyclic nucleotide binding. This kinetic fidelity of the cyclic 
nucleotide binding sites is dependent on an intact N-terminus 
[15]. Removal of the N-terminal 77 amino acids of PKG Is 
generated a constitutively active enzyme with altered cGMP- 
binding characteristics [15,16]. In analogy, deletion of the first 
91 amino acids of PKA Is abolished the cooperative binding 
of cAMP and modified the cAMP-binding constants [17]. The 
cGMP-binding characteristics in PKG Is also depend on the 
state of phosphorylation [14,18] and oxidization [19]. How- 
ever, the possible modulatory role of the catalytic domain 
on the cGMP-binding properties has not been addressed. 
Therefore, we expressed the regulatory domain of PKG I~ 
in E. coli, purified the recombinant mutant protein and stud- 
ied its cGMP-binding kinetics in order to identify the func- 
tional role of the catalytic domain more precisely. 
2. Materials and methods 
1. Introduction 
The domain structure of the cGMP-dependent protein ki- 
nase type Ic~ (PKG Ic0 consists of two independent functional 
elements. The N-terminal regulatory domain contains the di- 
merisation region followed by an auto-inhibitory sequence 
and two in-tandem cGMP-binding sites, whereas the ATP- 
and peptide substrate binding sites reside within the C-ter- 
minal catalytic domain of the enzyme [1-3]. The crystal struc- 
tures of the regulatory subunit [4,5] and the catalytic subunit 
[6-8] of the closest relative, the cAMP-dependent protein ki- 
nase type Is  (PKA Ic 0, have served as valuable structural 
models for the regulatory and catalytic domains of PKG Is 
([2] and Tsigelny and Dostmann, manuscript in preparation). 
However, the stereochemical relationship between the two 
domains remains unknown. Binding of cGMP to both 
cGMP-binding sites modulates the interaction between the 
domains which, in turn, leads to the activation of the enzyme. 
In contrast o PKA Is, the activation of PKG Is does not 
require the dissociation of the domains [9]. 
Although very similar in primary sequence, the cGMP- 
binding sites differ with respect o their binding kinetics and 
analog specificity [10-12]. Each PKG monomer consists of a 
low and a high affinity cGMP-binding site, referred to as site 
A (or site 2) and B (or site 1) [1,2]. cGMP site A is character- 
ized by the rapid dissociation of bound cGMP and an appar- 
ent KD of 110-150 nM, whereas cGMP site B shows a slow 
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2.1. Construction of ~352~570 PKG Ia 
A pUC18 derivative containing the full-length cDNA of PKG Ic¢ 
(pUC-PKG) was constructed as described previously [13]. The regu- 
latory domain of PKG was amplified using specific PCR primers: the 
forward primer 5'ATGTCACTCGTGAAGACT3' (bp 800-817) and 
the reverse primer 5'GCCGGGATCCTTAGGCGAAGAAAG- 
CAGCTTC3' (bp 1042-1059). This latter primer also contained a
non-annealing sequence which carried a STOP signal followed by a 
BamHI restriction site. The amplified DNA product was then digested 
with Bsu36I and BamHI to yield a fragment for ligation into Bsu36I/ 
BamHI cut pUC-PKG. Transformation f this ligation mixyure in E. 
coli JM101 and subsequent screening of positive transformants with 
specific PCR primers (above) yielded the plasmid pUC-A352-670 
PKG. After sequencing the amplified region [20], several colonies 
were picked and screened for high yields of A352~i70 PKG Ic~ expres- 
sion, by scanning the total cell extracts with SDS-PAGE and immuno- 
blotting. 
2.2. Expression and purification of 6352~570 and ~1-77/352~70 PKG 
Ict 
4 1 of LB-ampicillin were inoculated with E. coli JM101/pUC-A352- 
670 PKG and grown at 37°C for 24-48 h. The cell pellet was resus- 
pended in buffer A (25 mM KPO4 pH 6.6, 10 mM DTT, 5 mM 
EDTA, 5 mM EGTA, 10 mM benzamidine, I mM PMSF, 10 ~tg/ 
ml SBTI, 284 ~tM TPCK, 135 ~tM TLCK) and passed twice through a
French pressure cell at 4°C. All subsequent steps were performed at 
4°C. The homogenate was centrifuged for 30 min at 10000 rpm and 
the supernatant diluted with distilled water to the conductivity of 
buffer A (0.3 mS/cm) before application to a Whatman-DE52 ion- 
exchange column. A352-670 PKG and A1-77/352~70 PKG were 
eluted with a 0-250 mM NaC1 gradient in buffer A. Peak fractions 
of both proteins were pooled and applied to freshly synthesized 
cAMP-agarose column. Following an isocratic wash protocol with 
buffer A+I M NaC1, the proteins were eluted at room temperature 
in buffer A+I mM cAMP. The peak fractions were dialyzed against 
buffer B (10 mM KPO4 pH 6.6, 2 mM EDTA), concentrated to a 
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Fig. 1. Domain structure of PKG type Ic~ and several deletion mutants. The C-terminal deletion A352-670 PKG Ia was generated using PCR- 
overlap-extension a d purified from E. coli E222 cells. The double deletion protein A1-77/352-670 PKG Ia was co-purified as a proteolytic 
fragment. The N-terminal deletion A1-77 PKG Iot is shown for comparison and was characterized earlier [15,16]. The designation A and B for 
the slow and fast cGMP-binding sites is in accordance with previously published ata [26] and our own work (Dostmann et al., unpublished re- 
suits). 
volume of approx. 1.5 ml, and applied on a 5.5×7 cm 7.5% non- 
denaturing preparative polyacrylamide gel column (BioRad Prep cell 
model 491). Electrophoresis was carried out at 4°C and 300 V and 4- 
ml fractions were collected at 0.25 ml/min. A1-77/352-670 PKG was 
found in fractions 5-7 and A352-670 PKG eluted with fractions 8-11. 
2.3. Equilibrium cGMP-binding and cGMP exchange rates 
Equilibrium cGMP-binding constants (KD) for wild-type PKG and 
mutants A352-670 PKG and A1-77/352-670 PKG were determined by 
modification of a previously described method [21]. Proteins were 
incubated in buffer C (50 mM MES, pH 6.9, 0.4 mM EGTA, 1 mM 
Mg-acetate, 10 mM NaC1, 10 mM DTT and 0.5 mg/ml BSA) with 
varying concentrations of [3H]cGMP (30 Ci/mmol, Amersham). After 
90 min incubation at 0°C, aliquots were precipitated in 3 ml of ice- 
cold 95% ammonium sulfate (containing 10 mM HEPES-NaOH pH 
7.0, 2 mM EDTA) and filtered over 0.45 I.tm pore size nitrocellulose 
filters (Schleicher and Schuell). To distinguish the two kinetically dif- 
ferent cGMP-binding sites, [3H]cGMP bound to site A was selectively 
displaced by an excess of unlabeled cGMP as described previously 
[211. 
cGMP exchange rates (kd) were measured by incubating the pro- 
teins with excess [3H]cGMP for 90 min at 0°C in buffer D (50 mM 
MES pH 6.9, 0.5 mM EGTA, 1 mM Mg-acetate, 10 mM NaC1, 10 
mM DTT, 1 ~tM [3H]cGMP, 0.5 mg/ml BSA) [13]. For exchange rates 
with  "~1/2 ~ 30 S, cold cGMP was added to a final concentration f 100 
~tM in buffer E (15 mM HEPES-NaOH pH 7.0, 5 mM EDTA, 0.3 
mM EGTA, 20 mM DTT, 0.5 mg/ml BSA, 150 mM NaC1 and 1 mM 
cAMP). Aliquots were taken at various time points, precipitated in 
3 ml of ice-cold 95% ammonium sulfate and filtered over 0.45 ~tm 
nitrocellulose filters. For exchange rates with "q/2 -< 30 s the incuba- 
tion mixture was aliquoted in tubes, cold cGMP added and the reac- 
tion stopped by the addition of 3 ml of ice-cold 95% ammonium 
sulfate. In addition, 8-Br-cGMP which selectively binds to the slow 
dissociating site [11] was added to a final concentration of 10 lxM in 
experiments designated to measure selectively the fast dissociating 
binding site. 
The filters were washed twice with 3 ml of ice-cold 70% ammonium 
sulfate (10 mM HEPES pH 7.0, 2 mM EDTA), and dissolved in 10 ml 
scintillation fluid prior to counting. 
2.4. Sucrose density gradient ultracentrifugation 
5-15% sucrose density gradients were used to determine the Sved- 
berg constants (Sw,20). Centrifugation was carried out at 65 000 rpm 
for 108 min. Proteins (45-300 ~tg) were dissolved in buffer F (20 mM 
KPO4 pH 7.0, 2 mM benzamidine, 2 mM EGTA). The gradients were 
divided into 23 aliquots and protein concentrations were measured by 
either Bradford assay [22] or [3H]cGMP binding. The following inter- 
nal marker proteins were used: phosphorylase b (Sw20 = 8.2), y-globu- 
lin (rabbit, Sw,20 = 6.36), horseradish peroxidase (Sw20 = 3.67) and lyso- 
zyme (Sw,20 = 1.9). PKA regulatory subunit I was run as a control 
(sw,20 = 4.7) [23,24]. 
2.5. Miscellaneous methods 
cAMP-agarose was synthesized by coupling 25 ml N-hydroxysucci- 
nimide-activated agarose (Affigel, Bio-Rad) with 50 ~tmol 8-(2-ami- 
noethyl)-amino-cAMP (BioLog) in 100 mM HEPES pH 7.0 at 
room temperature under continuous haking. The reaction was com- 
plete after 60 min as was deduced from the absorbance of the super- 
natant at 273 rim. Unreacted groups were blocked with 100 ~tl 1 M 
ethanolamine, pH 8.0 for 90 min. The resin was stored in buffer 
A+0.05% Na-azide. 
Immunoblotting was performed by using specific antibodies raised 
against he N-terminus of the PKG Ice [25]. Purified or crude extract 
proteins were separated on 10-12% SDS-PAGE and blotted on PVDF 
membranes under semi-dry conditions (1 h, 0.8 mA/cm2). The mem- 
branes were treated as described previously [25] and the specifically 
bound antibodies visualized by an anti-rabbit IgG antibody conju- 
gated to alkaline phosphatase. 
For peptide sequencing the purified proteins were separated on 12% 
SDS-PAGE and transferred to PVDF membranes. The specific bands 
(approx. 1-3 p.g protein/band) were analyzed on a gas-phase sequen- 
cer. 
Non-denaturing PAGE was performed on 6% gels with the follow- 
ing buffer conditions: stacking el: 62.5 mM Tris-HC1, pH 6.8; sep- 
arating gel: 375 mM Tris-HC1, pH 8.9; running buffer: 25 mM Tris- 
HC1, pH 8.8, 52 mM glycine; 5 >(sample buffer: 312 mM Tris-HC1, 
pH 6.8, 50% glycerol, 0.05% bromophenol b ue. The gels were run at 
8-10 mA for 12-16 h and subsequently stained with Coomassie blue 
R250. 
3. Results 
3.1. Construction and purification of  the PKG Itx regulatory 
subunits 
The truncated form A352-670 PKG Ia  (Fig. 1) of the wild- 
type kinase coding for the N-terminal  352 amino acids was 
constructed using overlap-extension-PCR as outlined in Sec- 
t ion 2. Selected transformants were screened for expression by 
screening aliquots of the total cell extract by SDS-PAGE. 
Several colonies expressed large amounts of protein that mi- 
grated with a molecular mass of approx. 38 kDa (data not 
shown). Expressed A352-670 PKG Ia  was found in the super- 
natant  fraction as well as in the particulate fraction at a ratio 
of approx. 1:1 (data not shown). The supernatant fraction 
was applied to a DEAE ion-exchange column and those pro- 
tein fractions showing cGMP-b inding capacity were pooled 
and applied on a cAMP-affinity resin. Elution with 1 mM 
cAMP yielded two proteins with molecular masses of 38 
and 30 kDa, respectively, as deduced from SDS-PAGE (Fig. 
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Fig. 2. cAMP-agarose affinity chromatography of E. coli E222 
extracts. E. coli E222 was transformed with the vector coding for 
A352-670 PKG I(x, lysed, and the supernatant chromatographed on 
a DEAE-ion-exchange column (data not shown). Fractions which 
specifically bound [3H]cGMP were pooled and loaded on a freshly 
synthesized 8-AEA-cAMP-agarose column as outlined in Section 2. 
Cyclic nucleotide binding proteins were eluted with 1 mM cAMP 
and fractions 1-4 monitored by (A) SDS-PAGE, lanes 1-4 and (B) 
immuno-blotting with a specific antibody raised against the N-termi- 
nus of PKG type Ic~ [25]. Lane 1 shows native PKG Ice and lanes 
2 5, fractions 1-4. The proteins at 38 and 30 kDa were transferred 
onto PVDF membranes, ubjected to gas-phase sequencing and 
identified as A352-670 PKG Ia (38 kDa) and A1 77/352-670 PKG 
Ic~ (30 kDa). 
2A). Immuno-blot analysis of the cAMP-affinity column frac- 
tions revealed that only the 38 kDa band was detectable by a 
PKG Ia specific antibody. Since the antibody is directed 
against he N-terminal residues 13-35 of PKG Ia [25], the 
30 kDa band most likely reflected a proteolytic fragment of 
A352-670 PKG Ia, rather than protein contamination (Fig. 
2B). Gas-phase protein sequencing of the 38 kDa and 30 kDa 
proteins confirmed that the lower molecular mass protein was 
a tryptic degradation product of A352-670 PKG Ia (data not 
shown). The cleavage site was identified in the hinge region at 
Arg 77, an identical position to that described previously for 
native PKG Ia [15]. Complete suppression of degradation 
could not be achieved even when using efficient trypsin pro- 
tease inhibitors, partly because proteolysis already occurred 
during protein biosynthesis in the bacterium (data not 
shown). Apparently, the catalytic domain of PKG I~ protects 
the hinge region of the enzyme at Arg T7 from proteolysis. 
Preparative non-denaturing gel electrophoresis was applied 
to separate ffectively A352-670 PKG Ic~ from its A1-77 trun- 
cation fragment (Fig. 3). A 10 12 1 preparation yielded 6-10 
mg each of A352-670 PKG Ia and A1-77/352-670 PKG Ia 
purified to apparent homogeneity. 
3.2. Characterisation of  8352470 and 51-77/352~570 PKG Ia 
We next examined the structural features of the two recom- 
binant proteins. The native PKG Ia consisted of two proto- 
mers linked probably by a leucine zipper type hydrophobic 
interaction located at the N-terminus of each protomer [27]. 
In order to identify dimer formation of the deletion mutants 
we employed 5-15% sucrose density gradient ultracentrifuga- 
tion. Native PKG Ia showed a Svedberg constant of 7.6 S 
which was in accordance with earlier experiments [14]. Simi- 
larly, the regulatory subunit of PKA had the characteristics of 
a dimer with s20,w = 6.1 S [17,25]. However, A352-670 PKG Ia 
did not dimerize, as was indicated by a Svedberg constant of 
2.5 (Table 1). The monomeric state of A352-670 PKG Ia was 
further observed with non-denaturing PAGE (data not 
shown). The double deletion fragment A1-77/352-670 PKG 
Ia, which lacked the dimerisation site, had a Svedberg con- 
stant of 2.2, supporting the monomeric structure of A352-670 
PKG Ia. Thus, the catalytic domain influences not only the 
dimerization at N-terminus, but protects the hinge region 
from tryptic cleavage as well. 
To determine whether the recombinant PKG regulatory 
subunit possessed the ability to interact with the catalytic 
subunit of PKA, A352-670 PKG Ia was dialyzed in the pres- 
ence of a 10% excess of recombinant Ca under conditions that 
would typically lead to the formation of holoenzyme [28]. 
After 48 h no holoenzyme formation was detectable as dem- 
onstrated by non-denaturing gel electrophoresis and cAMP- 
dependent activation assays (data not shown). Additional at- 
tempts to express the catalytic domain of PKG Ia in E. coli in 
an active conformation were unsuccessful (Dostmann and 
Endres, unpublished results). 
The kinetic analysis of the deletion mutants is summarized 
in Table 1. Both A352-670 PKG Ia and A1-77/352-670 PKG 
Ia contained two functional cGMP-binding sites. However, 
their binding and dissociation characteristics differed clearly 
from those of the wild-type enzyme and another previously 
characterized N-terminal deletion mutant A1-77 PKG Ia 
[15,16]. While the exchange rates for the 'fast' site B differed 
only by a factor of 2 between wild-type and mutant A1-77/ 
Table 1 
Kinetic and hydrodynamic constants for wild-type and deletion mutants of PKG Ice 
PKG type 
Icta A352 670 A1 77/352-670 A1-77 b 
cGMP equilibrium binding, KD (nM) 
Site A (slow) 17.6 79 218 
Site B (fast) 109 ->500 218 
Hill coefficient (n) 1.4~1.6 0.95 
.0 
cGMP exchange rate, kd (min -1) 
Site A (slow) 0.0044 0.22 0.83 
Site B (fast) 3.46 6.52 6.60 
Molecular mass (kDa, SDS-PAGE) 75 38 30 
Svedberg constant, s20,w (S) 7.6 2.5 2.2 









Purified mutants A352-670 PKG I~ and A1-77/352-670 PKG hx were characterised as described under Section 2. 
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Fig. 3. Preparative non-denaturing polyacrylamide g l electrophor- 
esis was employed to separate A352-670 PKG Itx from the double 
deletion fragment A1 771352-670 PKG Ict. Pooled fractions from 
the cAMP-agarose column (Fig. 2) were applied to the gel following 
dialysis (Section 2). Typically, when running a 7.5% gel (5.5 cm+l.5 
cm stacking gel) at 300 V and 4°C the 30 kDa protein A1 77/352- 
670 PKG Ic~ eluted with fractions 5 and 6 and A352-670 PKG Ict 
(38 kDa) with fractions 9-12. 
352-670 PKG hx, we saw a far more dramatic effect on the 
'slow' site A. Deletion of the N-terminus (A1-77 PKG hx) 
increased the kd by a factor of 15, whereas deletion of the 
catalytic domain (A352-670 PKG Ict) shifted the cGMP ex- 
change rate 50-fold. More drastic was the effect on A1 77/ 
352 670 PKG Ict, the kd was shifted by a factor of 180. These 
findings demonstrate that the catalytic domain has a more 
pronounced effect on cGMP dissociation than the N-terminus 
does. This effect was also apparent for cGMP equilibrium 
binding to the proteins. While A1-77 PKG Ict had a 3-fold 
decreased cGMP affinity to site B, the constructs with the 
deleted catalytic subunit showed a similar effect on both sites 
A and B. For the mutant A352-670 PKG Ia, the low affinity 
site could not be measured exactly with the conventional m- 
monium sulfate filter assay, as has been noted previously [29]. 
However, by comparing the experimental results for A352-670 
PKG Ict and A1-77/352-670 PKG Ict with estimated equili- 
brium binding constants, consistently lower values for site A 
and B were found (data not shown). The stoichiometry of 
cGMP binding was 1.89 mol cGMP/mol protein for the dele- 
tion mutant A1-77/352-670 PKG and 0.5-1.3 mol cGMP/mol 
protein for A352-670 PKG Ict, again demonstrating our in- 
ability to detect this low affinity site adequately with the 
standard ammonium sulfate assay. In addition, we observed 
a loss of cooperativity for cGMP binding with all deletion 
mutants. This result is in accordance with observations from 
an N-terminal deletion mutant of the regulatory subunit of 
the PKA [17]. Apparently, even subtle changes on the domain 
structure flanking the cGMP-binding sites abolish completely 
the crosstalk between the sites [30]. 
4. D iscuss ion  
The results presented in this work demonstrate that the 
catalytic domain of the PKG Ict exerts an impact on three 
distinct regions of the N-terminal regulatory domain of the 
enzyme: (i) the dimerization region; (ii) the hinge region; and 
(iii) the cGMP-binding sites. 
At first, since dimerisation was abolished when the catalytic 
domain was deleted, a stabilizing influence on dimer forma- 
tion must be postulated for the catalytic domain. In contrast 
to PKA, dimer formation in PKG Ict occurs presumably via 
the hydrophobic forces of two N-terminal a-helices (amino 
acids 1-40) [27]. However, factors that could interfere with 
this interaction have not been identified. Since the catalytic 
domain of the enzyme is inhibited by an auto-inhibitory do- 
main (hinge region) [31] C-terminal of the ct-helix (amino 
acids 58-72) a steric connection between the dimerisation do- 
main and the catalytic domain appears possible. 
Secondly, the strong tendency for proteolytic leavage at 
residue Arg 77 indicates that, in fact, this stabilizing influence 
of the catalytic domain extends beyond the immediate N-ter- 
minus to the hinge region. Interestingly, auto-phosphorylation 
of PKG hx occurs at multiple positions [31], indicating that 
the hinge region is far more flexible in nature than the type II 
regulatory subunit of PKA [32]. Therefore, cleavage of the 
catalytic domain may leave the hinge region exposed and 
prone to proteolysis. 
Thirdly, the catalytic domain influences the cGMP-binding 
affinity of the cGMP-binding sites A and B. Our results show 
that both deletion mutants A352-670 PKG Ic~ and A1-77/352- 
670 PKG Ict, which lack the catalytic domain, possess two 
cGMP-binding sites which both showed reduced ligand bind- 
ing affinities and a loss of cooperative cGMP binding. Taken 
together, the data from this study and previously published 
results from N-terminal deletion mutants of PKA and PKG 
[15-17] suggest that the cGMP-binding affinity for each bind- 
ing site is regulated from regions outside the actual cGMP- 
binding domains. Therefore, the observed KD values in those 
mutants reflect the 'true' affinities for each site. These addi- 
tional regions are part of the N-and C-terminus; they comple- 
ment the cyclic nucleotide binding sites as well as influence 
cooperativity between the sites. 
In conclusion, the catalytic domain appears to affect all 
known distinct functional regions of the regulatory domain. 
Our results show that the catalytic domain of PKG Ic~ forms 
an intimate contact with its own regulatory domain demon- 
strating the compactness of the enzyme. Elucidation of the 
structural nature of this interaction, however, must wait until 
a crystal structure of PKG hx becomes available. 
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